Navigating Life Sciences: M&A and the Path to IPO
IPO markets are reopening. M&A is accelerating. For life sciences companies, the question is no longer whether opportunities exist—it's how to seize them.
On 23 September 2026, Winston Taylor and Raymond James are bringing together senior leaders to dig into the routes to growth, liquidity, and exit in life sciences.
Over the past year, US biotech markets have shown renewed momentum—more IPO activity, reverse mergers, and a wave of high-value acquisitions. For UK companies, that means new opportunities and harder decisions.
When is the right time to raise capital? What drives valuation? And how do you build a business that's attractive to both investors and acquirers?
What we'll cover:
- IPO or M&A? How to make the call and get the timing right.
- What investors look for when backing growth-stage companies.
- The milestones that drive valuation and strategic interest.
- Building optionality in uncertain markets.
- What recent deals tell us about where the market is heading.
- How to position your business for what's next in 2026 and 2027.
Hear from guest speakers Iqbal Hussain (formerly of Centessa Pharmaceuticals), Alex Hammacher (Oxford Science Enterprises), and Jamie Heath (Apollo Therapeutics).
Agenda
Registration and networking from 5pm
Panel discussion - 5.50pm
Drinks and networking - 7pm
Register your interest here.
